XML 57 R34.htm IDEA: XBRL DOCUMENT
v3.25.2

Acquisitions and License Agreements (Additional Information) (Details) - USD ($) |  |  |  | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Feb. 22, 2025 | Jun. 14, 2022 | May 31, 2022 | Mar. 31, 2025 | Mar. 31, 2024 | Dec. 31, 2024 | Dec. 31, 2023 | Feb. 28, 2025
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Royalty expenses |  |  |  | $ 100,000 | $ 0 | $ 300,000 | $ 26,000 |
Payment to acquire license |  |  |  | 0 |  | 0 |  |
Accrued Royalty Payables |  |  |  | 100,000 |  | 100,000 | 5,000 |
Tlido Rest Of World License Agreement [Member] |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Percentage of Lidocaine Topical System | 1.80% |  |  |  |  |  |  |
Aggregate Payment Of Company | $ 200,000 |  |  |  |  |  |  |
Gloperba Rest of World License Agreement [Member] |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Revenue, Remaining Performance Obligation, Percentage |  |  |  |  |  |  |  | 50.00%
Elyxyb Rest of World License Agreement [Member] |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Revenue, Remaining Performance Obligation, Percentage |  |  |  |  |  |  |  | 50.00%
Patents [Member] | Sorrento [Member] |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Payment upon the achievement of net sales |  |  | $ 20,000,000 |  |  |  |  |
Amount due for New Drug Application |  |  | $ 3,000,000 |  |  |  |  |
Scilex Pharma [Member] | Tlido Rest Of World License Agreement [Member] |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Revenue, Remaining Performance Obligation, Percentage | 50.00% |  |  |  |  |  |  |
License Agreement |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Development milestones payment was recognized under other long-term liabilities |  |  |  | 200,000 |  | 200,000 | 200,000 |
License Agreement | Romeg License Agreement [Member] |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Up-front license fee |  | $ 2,000,000 |  |  |  |  |  |
Payment upon the achievement of net sales |  | 13,000,000 |  |  |  |  |  |
Payments for royalties |  | 150,000 |  |  |  |  |  |
Non-Refundable, Non-Creditable Payment |  | $ 700,000 |  |  |  |  |  |
Transfer of Common Stock Shares |  | 22,267 |  |  |  |  |  |
Intangible asset |  | $ 5,700,000 |  |  |  |  |  |
Deferred consideration |  | $ 3,700,000 |  |  |  |  |  |
Royalty expenses |  |  |  | $ 200,000 | $ 200,000 | 600,000 | 300,000 |
Contingent consideration, liability |  |  |  |  |  | $ 0 | $ 0 |

X
- Definition Accrued Royalty Payables + References No definition available. + Details
Name: | sclx_AccruedRoyaltyPayables
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate Payment Of Company + References No definition available. + Details
Name: | sclx_AggregatePaymentOfCompany
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount due for New Drug Application + References No definition available. + Details
Name: | sclx_AmountDueForNewDrugApplication
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition DeferredConsiderationLiabilities + References No definition available. + Details
Name: | sclx_Deferredconsiderationliabilities
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Non-Refundable, Non-Creditable Payment + References No definition available. + Details
Name: | sclx_Non-RefundableNon-CreditablePayment
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment to Acquire License + References No definition available. + Details
Name: | sclx_PaymentToAcquireLicense
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment Upon The Achievement of Net Sales + References No definition available. + Details
Name: | sclx_PaymentUponTheAchievementOfNetSales
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of Lidocaine Topical System + References No definition available. + Details
Name: | sclx_PercentageOfLidocaineTopicalSystem
Namespace Prefix: | sclx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Transfer of Common Stock Shares + References No definition available. + Details
Name: | sclx_TransferOfCommonStockShares
Namespace Prefix: | sclx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition UpFrontLicenseFee + References No definition available. + Details
Name: | sclx_Upfrontlicensefee
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sclx_GloperbaRestOfWorldLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sclx_ElyxybRestOfWorldLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_ScilexPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |